Embecta (Nasdaq:EMBC) shares got a boost today on first-quarter results that beat the consensus Wall Street forecast.
Shares of EMBC rose 6.5% to $12.09 apiece in early-morning trading today.
The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $44.1 million. That equals 74¢ per share on sales of $261.2 million for the three months ended Dec. 31, 2025.
Embecta recorded a bottom-line gain from breakeven in the same period a year ago on a sales decline of 0.3%.
Adjusted to exclude one-time items, earnings per share came in at 71¢. That landed 4¢ ahead of expectations on Wall Street. Sales also topped the forecast as experts projected $258.1 million in revenue.
Embecta said it continued to strengthen its core business through its brand transition program in international markets. It expects “significant completion” for this process by the end of calendar year 2026. The company also said it strengthened its U.S. Medicare business with a new payer.
Additionally, Embecta — one of the largest diabetes tech companies in the world — said it finalized product design and completed assembly line equipment installation for market-appropriate pen needles and syringes. It now has the manufacturing validation process underway.
On the product portfolio front, Embecta said it advanced more than a third of the more than 30 identified potential B2B generic partners into either contract negotiations or executed contracts. It continues to make progress on expanding availability of appropriately sized GLP-1 retail packaging, too.
Read more about Embecta and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Embecta also said that it paid down approximately $37.5 million in debt. The company reaffirmed its guidance for 2026, projecting between $1.071 billion and $1.093 billion in sales and adjusted EPS between $2.80 and $3.
“During the first quarter our results were largely consistent with our expectations,” said Devdatt (Dev) Kurdikar, president and
CEO of Embecta. “As we look ahead, we remain focused on pursuing initiatives that will transform the company into a broad-based medical supplies company which serves chronic care patients and drug delivery partners. This includes maintaining our global leadership position in core injection products, expanding our product portfolio, and creating additional financial flexibility through ongoing debt reduction.
“Given our performance during the first quarter, coupled with our outlook for the remainder of the year, we are maintaining our previously provided guidance for key financial reporting metrics.”
The analysts’ take
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang maintained a “Buy” rating for Embecta following the earnings results.
The analysts highlighted strength in the company’s international business, including EMEA, Latin America and Asia-Pacific (excluding China). However, they note offsetting declines in the U.S. due to lower U.S. pricing from customers and competition, plus lower volumes from channel dynamics.
Despite maintained guidance, the analysts expect U.S. pricing headwinds to push numbers toward the bottom of Embecta’s provided range. Still, they expect pricing concessions to solidify U.S. volume growth as global momentum continues and China efforts recover.
“In our view, [Embecta] continues to execute on its financial targets while navigating macroeconomic and market pressures,” the analysts said.
